Brian P. Monahan

Q: What Schools Are Affiliated With Brian P. Monahan

Brian P. Monahan is affiliated with the following schools: Fairfield University, Case Western Reserve University, Uniformed Services University of the Health Sciences, Harvard University

Brian P. Monahan's AcademicInfluence.com Rankings

Brian P. Monahan

Philosophy

#11111

World Rank

#15253

Historical Rank

#2101

USA Rank

Logic

#10368

World Rank

#13313

Historical Rank

#1956

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Brian P. Monahan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Brian Patrick Monahan is the Attending Physician of the United States Congress and the United States Supreme Court and holds the rank of rear admiral in the United States Navy. Monahan was nominated to the position and rank by United States President Barack Obama in January 2009. He previously served as the director of hematology and medical oncology at the National Naval Medical Center. He is a Master of The American College of Physicians and a Member of the Academy of Medicine.

(See a Problem?)

Brian P. Monahan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Torsades de pointes occurring in association with terfenadine use. (1990) (553)
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (1999) (290)
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. (2003) (112)
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. (2000) (58)
Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. (1999) (57)
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors (2010) (48)
Clinical significance of the FV:Q506 mutation in unselected oncology patients. (1996) (46)
Necrotizing enterocolitis in neutropenia and chemotherapy: A clinical update and old lessons relearned (2006) (31)
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. (2000) (22)
Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy (2003) (18)
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule (2003) (15)
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion (2000) (14)
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients (2001) (12)
A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors (2005) (9)
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. (2002) (8)
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. (1999) (7)
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin (2003) (7)
Clinical aspects of expression of inversion 16 chromosomal fusion transcript CBFB/MYH11 in acute myelogenous leukemia subtype M1 with abnormal bone marrow eosinophilia. (1996) (6)
Extraocular muscle palsy from metastatic prostate cancer. (2003) (4)
Mistletoe extract/gemcitabine combination treatment: An interim report from the NCCAM/NCI phase I study in patients with advanced solid tumors (2005) (4)
Erratum to “NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors” (2014) (3)
The evolution of fine-scale boundaries on 15 June 2002 during IHOP (2005) (0)
APhase IPharmacologic and PharmacogeneticTrial of Sequential 24-Hour Infusion of Irinotecan Followedby Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with SolidTumors (2005) (0)
Phase I a nd P harmacokinetic T rial o f W eekly O ral Fluorouracil G iven W ith E niluracil a nd Low-Dose L eucovorin t o P atients W ith S olid T umors (2013) (0)
Phase I and Pharmacokinet ic Tria l o f Weekly Oral Fluorourac i l Given With Eni lurac i l and Low-Dose Leucovor in to Pat ients With Sol id Tumors (2000) (0)
Erratum: NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors (Evidence-based Complementary and Alternative Medicine) (2014) (0)

This paper list is powered by the following services:

Other Resources About Brian P. Monahan

en.wikipedia.org

What Schools Are Affiliated With Brian P. Monahan?

Brian P. Monahan is affiliated with the following schools:

Brian P. Monahan's Academic­Influence.com Rankings